Home » Stocks » ADVM

Adverum Biotechnologies, Inc. (ADVM)

Stock Price: $3.78 USD 0.09 (2.44%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 370.16M
Revenue (ttm) 7.50M
Net Income (ttm) -123.04M
Shares Out 97.75M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.78
Previous Close $3.69
Change ($) 0.09
Change (%) 2.44%
Day's Open 3.64
Day's Range 3.60 - 3.87
Day's Volume 3,347,478
52-Week Range 3.46 - 26.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...

3 days ago - GlobeNewsWire

Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...

Other stocks mentioned: AKBA
3 days ago - GuruFocus

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

3 days ago - Business Wire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

5 days ago - Business Wire

Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced new long-term data from the OPTIC Phase 1 trial of ADVM-022 single intravitreal (IVT) injection gene therapy in patients with neovascular or wet ...

6 days ago - Benzinga

-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --

1 week ago - GlobeNewsWire

Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022...

1 week ago - Benzinga

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

1 week ago - Business Wire

Investors are running for the hills following the company's latest clinical update.

1 week ago - The Motley Fool

REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant d...

1 week ago - GlobeNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

1 week ago - Business Wire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 weeks ago - Business Wire

Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.

2 weeks ago - GlobeNewsWire

Sonic's Nominees Lack Experience and Qualifications to Advance Adverum's Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy

2 weeks ago - GlobeNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 weeks ago - Business Wire

-- Adverum to host webcast with key opinion leaders on  Sunday, May 2, 2021 at 7:00 AM PT --  REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a cli...

3 weeks ago - GlobeNewsWire

HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the...

1 month ago - PRNewsWire

-- Anand Reddi appointed vice president, patient advocacy, access, and  digital innovation -- -- Bill Tan, PharmD, appointed vice president,  clinical operations program lead --

1 month ago - GlobeNewsWire

REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...

1 month ago - GlobeNewsWire

Responds to Intent to Nominate Directors from Sonic Fund

1 month ago - GlobeNewsWire

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA --

2 months ago - GlobeNewsWire

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call Key Opinion Leader Arshad ...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

2 months ago - GlobeNewsWire

Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regu...

3 months ago - Forbes

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with tota...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

5 months ago - GlobeNewsWire

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after  a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 months in C...

5 months ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on  Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , November 14 ...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.

7 months ago - Seeking Alpha

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases...

7 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t...

8 months ago - GlobeNewsWire

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...

8 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...

8 months ago - GlobeNewsWire

Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...

9 months ago - GlobeNewsWire

-- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Adver...

9 months ago - GlobeNewsWire

-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops -- -- Data from all four cohorts planned by the end of 2020 --

10 months ago - GlobeNewsWire

-- Plans underway to begin expansion of manufacturing capabilities -- REDWOOD CITY, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene the...

10 months ago - GlobeNewsWire

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 31, 2014
CEO
Leone Patterson
Employees
167
Stock Exchange
NASDAQ
Ticker Symbol
ADVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 10.63, which is an increase of 181.22% from the latest price.

Price Target
$10.63
(181.22% upside)
Analyst Consensus: Buy